Respiratory syncytial virus (RSV) is the most common pathogen that causes lower respiratory tract infection of in children under 5 years of age, accounting for about 30% of all respiratory pathogens, and seriously endangering children's health. On May 22, the reporter learned from Nanjing Medical University that Li Youwen, a professor at the School of Public Health and a member of the Working Group on the Value of RSV Vaccine in the World Health Organization, Li Youwen, UN , and many scholars from the United Nations , published a paper in the international authoritative academic journal "The Lancet", saying that after systematically analyzing 481 studies involving RSV-related lower respiratory tract infections in children under 5 years old, they found that babies within 6 months of age are the group with the heaviest burden of lower respiratory tract infections in RSV, accounting for 20% of the infections, 39% of the hospitalizations, and 46% of the deaths. The so-called disease burden refers to the incidence, hospitalization rate and mortality rate of lower respiratory tract infection of RSV. It is reported that there is currently no effective antiviral drugs and other specific treatment methods for RSV lower respiratory tract infection, and some RSV vaccines and preventive antibodies are expected to be approved for use within the next 1 to 3 years. (Reporter Jin Feng of Science and Technology Daily)
Source: Science and Technology Daily
